Skip to content
DraconiticResearch
Search Sources API
210,049 studies31 sourcesUpdated 14 min ago

Oncology

5,302 studies557 in 7 days2,546 in 30 days

Filters
Type
Date
Clear

Latest

5,302 studies

  1. Efficacy of Tumor Treating Fields (TTFields) in triple negative breast cancer cells and synergy with PARP inhibitor talazoparib
    M. Ghandali, P. Srinivasan, S. Zhang +11
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  2. Reduced emerin expression marks gastric cancer progression and invasive nuclear remodeling
    Emily Hansen, Bovey Liu, James M. Holaska
    bioRxivPreprintCC BY-NCFull textOncologybioRxivPMC
  3. Positive selection and structural disruption of KCNA5 by mutation in colorectal cancer
    B. Xu, D. Shorthouse
    bioRxivPreprintCC BYFull textOncologybioRxiv
  4. A reference-calibrated spatial-statistical framework for quantifying stroma-tumor cell spatial associations from histology and its geometric limits
    T. Miti, D. Miroshnychenko, B. Desai +2
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  5. Radiotherapy Reshapes the 3D Genome in Medulloblastoma Cells
    D. R. Challis, R. Wilson, S. M. Navickas +5
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  6. Trastuzumab deruxtecan kills skin and uveal melanoma in vivo by HER2-independent payload release
    L. M. Nilsson, E. S. Tanaydin, S. Stenqvist +3
    bioRxivPreprintCC BYFull textOncologybioRxiv
  7. Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer.
    Atif Kamil, Sara Cowles, Casaundra C Driver +6
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  8. Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.
    Zhihan Zhang, Bingchun Chen, Hanmei Jiang +5
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  9. Interpretable Machine Learning Prognostic Model Integrating Inflammatory-Nutritional Biomarkers for Post-Prostatectomy Biochemical Recurrence: Development, Internal Validation, and Translational Target Exploration.
    Hao Wang, Yifei Zhang, Zhen Li +5
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  10. Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions.
    Hannah Hyde, Emma Mageau, Chelsea M Leduc +8
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  11. Multimodal Machine Learning-Based Clinical and Genomic Prognostic Factors for Progression-Free Survival in Metastatic Breast Cancer Using Phase III MONALEESA Trials
    C. Wang, R. Paul, Y. Li +20
    medRxivPreprintCC BY-NC-NDFull textOncologymedRxiv
  12. Methylation-defined tumour subgroups guide recognition of genetic predisposition in Wilms tumour
    F. Oberhammer, S. E. van Peer, N. B. Buter +9
    medRxivPreprintCC BYFull textOncologymedRxiv
  13. Prognostic value of the Hippo signaling pathway in oral squamous cell carcinoma: a systematic review and meta-analysis
    Igor Felipe Pereira Lima, Leonardo da Silva Bittencourt, Petra Gonçalves Reinehr +2
    medRxivPreprintAll rights reservedFull textOncologymedRxivPMC
  14. Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective Observational Real-World Cohort in Johannesburg, South Africa
    S. Amod, M. Tunmer, L. Campbell-Roper +6
    medRxivPreprintCC BYFull textOncologymedRxiv
  15. Initial psychometric evaluation of the Lipedema Quality of Life questionnaire in females with lipedema in Norway.
    Julianne Lundanes, John Roger Andersen, Jutta Dierkes +2
    Frontiers in global women's healthPeer-reviewedCC BYFull textOncologyEurope PMC
  16. Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
    Sha Liu, Junjun Lu, Zhaojie Lyu +7
    ImmunotherapyPeer-reviewedLicence not statedFull textOncologyPMC
  17. Nodal evaluation as the arbiter of oncologic equivalence: reassessing segmentectomy after CALGB 140503 and JCOG0802
    Akbar Bazarbaev, Vasiliki Androutsopoulou, Prokopis-Andreas Zotos +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  18. The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial design
    Luca Bertolaccini, Monica Casiraghi, Antonio Mazzella +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  19. Health-related quality of life and associated factors among individuals with cancer in Laos
    Nithaya Xatakoune, Lena J. Lee, Hohyun Seong +4
    Frontiers in public healthPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  20. Liquid biopsy in pancreatic ductal adenocarcinoma from diagnostic accuracy to clinical utility
    Konstantinos Kossenas, Nikolaos Garmpis, Nikolaos Karountzos +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  21. A large animal lung cancer model for the evaluation of intratumoural cisplatin delivery strategies
    James Meehan, David Collie, Ziyuan Chang +16
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  22. From armed-conflict to care: clinical outcomes, diagnostic challenges, and psychosocial burden in children evaluated for suspected cancer displaced from Gaza and treated at a regional center of excellence
    Rawad Rihani, Shrouq Amer, Maha Barbar +5
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  23. Durable partial response with low-dose, intermittent nivolumab in combination with gemcitabine for high PD-L1 metastatic triple-negative breast cancer: a case report
    Po Lin Ooi, Jamin Munchar Elias, Francis Yew Fu Tieng
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  24. Admission platelet-to-hemoglobin ratio and 1-year outcomes after percutaneous coronary intervention: a multicenter registry cohort study
    Jeong Tae Byoun, Donghyeon Joo, Sungho Jo +2
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  25. A novel CAF-related gene signature for prognostic and immunotherapy response prediction in PDAC based on single-cell RNA-seq and bulk RNA-seq data
    Xuezhi Du, Zesheng Li, Yuwei Wang +3
    Frontiers in pharmacologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref